Knowledge, attitudes, perceptions, and COVID-19 hesitancy in a large public university in Mexico city during the early vaccination rollout

Norma Mongua-Rodríguez¹, Mauricio Rodríguez-Álvarez², Daniela De-la-Rosa-Zamboni³, María Eugenia Jiménez-Corona⁴, Martha Lucia Castañeda-Cediel⁵, Guadalupe Miranda-Novales⁶, Gustavo Cruz-Pacheco⁷, Elizabeth Ferreira-Guerrero¹, Leticia Ferreyra-Reyes¹, Guadalupe Delgado-Sánchez¹, Maribel Martínez-Hernández¹, Arturo Cruz-Salgado¹, Rogelio Pérez-Padilla⁶, Samuel Ponce-de-León² and Lourdes García-García¹,9*

Abstract

Background Vaccination against COVID-19 is a primary tool for controlling the pandemic. However, the spread of vaccine hesitancy constitutes a significant threat to reverse progress in preventing the disease. Studies conducted in Mexico have revealed that vaccination intention in Mexico among the general population ranges from 62 to 82%.

Objective To know the prevalence of COVID-19 vaccine hesitancy and associated factors among academics, students, and administrative personnel of a public university in Mexico City.

Methods We administered an online survey investigating sociodemographic aspects, knowledge, attitudes, practices, and acceptance/hesitancy regarding the COVID-19 vaccine. Using generalized linear Poisson models, we analyzed factors associated with vaccine hesitancy, defined as not intending to be vaccinated within the following six months or refusing vaccination.

Results During May and June 2021, we studied 840 people, prevalence of vaccine hesitancy was 6%. Hesitancy was significantly associated with fear of adverse effects, distrust of physician's recommendations, lack of knowledge regarding handwashing, age younger than 40 years, refusal to use face masks, and not having received influenza vaccination during the two previous seasons.

Conclusions Vaccine hesitancy in this population is low. Furthermore, our results allowed us the identification of characteristics that can improve vaccine promotion.

*Correspondence: Lourdes García-Garcia garciarml@gmail.com

Full list of author information is available at the end of the article.
Background

From its appearance in December 2019 to November 2021, SARS-CoV-2 has caused more than 245 million cases of coronavirus disease 2019 (COVID-19) and 5 million deaths worldwide [1]. Up to the end of 2021, the impact of COVID-19 in Mexico had been devastating, with mortality rates (2,256.6 deaths per million inhabitants) and excess mortality (41.45% excess deaths from all causes compared to projection based on previous years) that ranked 24th and 5th among 210 countries [1].

The World Health Organization considers vaccination one of the most cost-effective ways of preventing disease. It currently prevents 2–3 million deaths a year, and a further 1.5 million could be avoided if global coverage of vaccinations improved [2]. Up to February 2021, more than 50 COVID-19 vaccine candidates had been developed [3]. The efficacy of the different vaccines has ranged from 50% to 95% against symptomatic COVID-19. This has resulted in more than one hundred countries approving or authorizing the emergency use of these vaccines between December 2020 and February 2021 [1].

Based on WHO guidelines, Mexico’s Covid-19 Vaccine Technical Advisory Group issued recommendations for Covid vaccination based on groups that would receive the most significant benefit of immunization, initially prioritizing health workers and people aged 60 years or older with or without comorbidities, people aged 50 to 59 years with comorbidities subsequently descending every decade of life, to continue the vaccination in the remaining population [4]. Up to the submission of this study, none of the vaccines available in Mexico could be used in people under 12 years of age, for which a specific stage was not yet contemplated for this population. SARS-CoV-2 vaccination was initiated in December 2020. Up to March 2022, the regulatory agency in Mexico (Federal Commission of Protection of Sanitary Risks, COFEPRIS) has agreements with the following pharmaceutical companies: Pfizer-BioNTech, Cansino, COVAX, AstraZeneca, Sputnik V, Sinovac, Janssen, and Moderna. COVID-19 vaccination in Mexico has been free and voluntary [5]. By November 2021, 58.9% of the Mexican population had been vaccinated with at least one dose of the COVID-19 vaccine [1].

The challenge to achieve high vaccination coverage has required political will, equity, solidarity, and rigorous planning for production, purchase, reception, and storage. However, the success of any vaccine depends on the proportion of the population that gets vaccinated. The SAGE Working Group on Vaccination Hesitancy was an important forum established in 2012 to map the determinants of vaccination hesitancy and recommend strategies to address what was finally recognized as a growing problem. This group concluded that vaccine hesitancy refers to delayed acceptance or refusal of vaccination despite the availability of vaccination services. Vaccine hesitancy is complex and context-specific, varying by time, place, and vaccines. It is influenced by factors such as complacency, convenience, and trust [6].

Several reviews have shown a wide variety of COVID-19 vaccine hesitancy worldwide. In a review of 82 studies, Shakeel et al. revealed variations in vaccine acceptance among adults ranging from 27.0% in the Republic of Congo to 97% in Ecuador. Low vaccine acceptance was associated with low education and awareness levels and inefficient government efforts and initiatives. Furthermore, poor influenza-vaccination history, conspiracy theories relating to infertility, and misinformation about the COVID-19 vaccine on social media also resulted in vaccine hesitancy [7]. Another review analyzed surveys in 114 countries/territories. COVID-19 vaccine acceptance rates ≥60% were seen in 72/114 countries/territories, compared to 42 countries/territories with rates between 13% and 59%. COVID-19 vaccine hesitancy appeared more pronounced in the Middle East/North Africa, Europe and Central Asia, and Western/Central Africa [8]. Nehal et al. included 63 studies in 30 countries, finding that global acceptance of the vaccine was 66.0% [9]. Focusing on low- and lower-middle-income countries, Patwary et al. reviewed 36 studies, including 83,867 respondents. The pooled-effect size of the COVID-19 vaccine hesitancy rate was 38.2%. Being male and perceiving the risk of COVID-19 infection were predictors of willingness to accept the vaccine [10]. Bono et al. studied 10,491 participants in 83 low- and middle-income countries, with results showing that acceptance was 88.8% overall, higher in Brazil, the only American country included in the study, than in other Asian and African countries [11]. Urrunaga et al. studied 472,521 participants in Latin America, with 80% intention to vaccinate, with Mexico ranking higher with 88.4% [12]. Mexican studies have examined the general population, among whom vaccination intention ranges from 62 to 82% [12–14]. We hypothesized that COVID-19 hesitancy among academics, students, and administrative personnel of a public university in Mexico City would be lower than among the general population. We also aimed to analyze hesitancy-associated factors.

Methodology

We administered an online survey to students, faculty, and administrative personnel of the National Autonomous University in Mexico. Participation was anonymous and voluntary. Participants completed an online survey between May 20 and June 27, 2021. The survey was available on a virtual platform on the university web page and shared in e-mails and social networks [15].
We used convenience sampling, including only people over 18 years of age, with the capacity to answer a self-administered questionnaire and who voluntarily agreed to participate.

The survey was designed by a multidisciplinary research team (infectious disease specialists, epidemiologists, public health specialists, communicators, designers, and computer scientists). The instrument was piloted among university workers, and a panel of experts reviewed the items and questions.

We followed the recommendations of the Sage Working Group on Vaccine Hesitancy, which grouped the factors influencing vaccine hesitancy into three categories: contextual, individual, and group, and vaccine/vaccination-specific influences [6]. We aimed to identify the following aspects that promote vaccine hesitancy or acceptance: demographic factors, personal responsibility and risk perceptions, preventive measures based on the perceived risk, trust in health authorities and vaccines, safety and efficacy of a new vaccine, and lack of information or vaccine misinformation [16]. The survey consisted of 23 questions that included socio-demographic aspects of the participant (age, sex, educational level, trade or job, perception of remuneration for the work performed); status of contacts concerning COVID-19; comorbidities (DM, hypertension, or obesity); knowledge about COVID-19; attitudes or perceptions towards COVID and self-care practices including the intention to be vaccinated and the reasons involved in the decision to get vaccinated. These questions were presented with dichotomous, multiple-choice, or Likert-scale answer options. Questions varied in format, but most used a 5-point Likert response scale ranging from strongly agree to disagree strongly (Cronbach α range, 0.75).

The following questions explored vaccine hesitancy/acceptance: “Would you get the COVID-19 vaccine? (answer options: Yes, No, I don’t know, I already got vaccinated) and “When would you get vaccinated against COVID-19? ” (Answer options: immediately; between 1 and 6 months; between 6 months and one year; between 1 and 2 years; after two years; never; other). Participants were hesitant when they answered that they did not want to be vaccinated, were doubtful, or would delay vaccination for more than six months. Vaccine acceptance was considered if the participant had already been vaccinated, was willing to get vaccinated, and intended to immediately receive the vaccine as soon as it was available for their age group.

We included participants who answered questions regarding their intention to be vaccinated and provided a valid zip code. We compared the characteristics of participants with those of non-participants.

Responses regarding knowledge about COVID-19; attitudes or perceptions towards COVID, and self-care practices were categorized into two groups: Those who agreed (“total agreement” or “partially agreement”) and those who disagreed (“neither agreeing nor disagreeing,” “partially disagreeing,” “totally disagreeing,” and “does not know” or “does not answer”). Participants’ characteristics are presented as mean (standard deviation (SD) for continuous measures with normal distribution, while categorical variables are presented as absolute (No) and relative (%) frequencies. We used the chi-square or Mann-Whitney test to compare participant characteristics according to hesitancy/acceptance. We constructed generalized linear Poisson models to investigate vaccine hesitancy/acceptance variables. Variables were entered into the models according to their statistical significance in the bivariate analysis (p ≤ 0.2) and their biological relevance and were retained based on the x² test of the log-likelihood ratios. A two-sided P value of less than 0.05 indicates statistical significance in all analyses[17]. Statistical analysis was done using the STATA statistical package version 15.

Results
One thousand ninety-one participants submitted their questionnaire, of whom 182 (16.68%) did not provide information about their zip code, and 69 (6.32%) did not answer questions about their intent to be vaccinated. Therefore, we analyzed 840 (76.99%) participants. Most lived in Mexico City (70.41%) and the State of Mexico (11.88%). (Fig. 1).

A comparison of the study population with those that did not provide complete information revealed that there were no statistical differences regarding sex, age group, formal education, type of occupation, comorbidities (DM, hypertension, or obesity), history of influenza vaccination in two previous seasons and history of tetanus vaccination. Individuals who referred to having a paid job or who had been in contact with a person ill or dead from COVID-19 were more likely to send complete information (Table 1).

x² test; No=number

Almost 6% of the participants were hesitant about receiving the vaccine. Crude analyses showed that vaccine hesitancy was associated with younger age, fewer years of formal education, unpaid work, having suffered from Covid-19, not having been diagnosed with hypertension, and not having received influenza vaccine during the two previous winter seasons. Table 2.

x² test; No=number.

Hesitant participants were more likely to lack knowledge regarding the transmissible nature of the disease or the severity of COVID-19 among people with comorbidities, were less afraid of falling ill, were uncomfortable or ashamed when wearing a facemask, distrusted physician or family’s recommendations did not believe that the
vaccine is useful or considered immunization unnecessary, feared adverse effects, referred having had bad experiences with other vaccines, would never vaccinate their children and refused to use facemasks, Table 3.

Adjusted analysis showed that vaccine hesitancy was significantly associated with fear of adverse effects, distrust of physician’s recommendations, lack of knowledge regarding handwashing, age younger than 40 years, refusal to use face masks, and not having received influenza vaccination during the two previous seasons, Table 4.

*Generalized Poisson linear model; PR=Prevalence Ratio.

**Discussion**

The results of our study highlight the high acceptance rates (96%) of vaccination among academics, students, and administrative personnel of a public university in Mexico City.

Our findings contrast with two nationally representative surveys conducted at the end of 2020 among Mexican adults that showed COVID-19 vaccine acceptance of 62.3% and 82%, respectively [13, 18]. The higher acceptance rates in our study conducted almost six months later may be due to increasing trends of vaccine acceptance over time after intense vaccine promotion campaigns and high hospitalization and mortality rates due to COVID-19. Different studies have described changes in acceptance or rejection trends over time. Sallam et al. reported that acceptance increased from 56.9% in April 2020 to 75.4% in June in the United States [19]. On the other hand, the survey of several European countries by Neumann-Böhme et al. reported a 20% decrease in acceptance during their study period [20]. As described previously for the Mexican population [13], we found that unpaid work and fewer years of formal education were associated with COVID-19 vaccine hesitancy by bivariate analysis.

Our definition of hesitancy allowed us to encompass individuals who refuse vaccination and those who have doubts about being vaccinated in the short term. This definition enables better feedback for public policies since it considers factors related to trust, perceived effectiveness, and convenience [6]. Diverse studies suggest that the decision to be vaccinated varies according to the disease, the type of vaccine, the target population (age, level of schooling, race, ethnicity), the particular socioeconomic context, the country’s income, the existence of legal regulations regarding vaccination, vaccine access and professional information [21–23]; additionally, different definitions of vaccine acceptance, hesitancy, and refusal influence the results.

An advantage of our study was that we explored reasons for hesitancy. We found that the main reason for vaccine hesitancy was fear of adverse effects. This factor has been widely described in the literature [11, 12, 22–24].

Our results underline the importance that the population links to the recommendation of the medical
personnel. Participants who distrusted physicians’ recommendations were nearly four times more likely to refuse the vaccine. Nehal et al. described that vaccine guidance was relevant, both from the members of participants’ social networks and those of their physicians [9]. According to several authors, trust refers to the attitude towards the vaccine advice from health personnel or community leaders [12]. Different studies have documented the usefulness of the person-centered health care model in changing behaviors and attitudes. The benefit of the model is based on health personnel’s willingness to listen and privilege the preferences, needs, and individual values of the person who consults them [6].

### Table 1 Characteristics of the studied population compared to those who did not accept participation or with incomplete information

| Characteristics                        | Studied No (840) | % (76.99) | Not Studied No (251) | % (23.01) | P-value* |
|----------------------------------------|------------------|-----------|----------------------|-----------|----------|
| Male                                   | 268/839          | 31.94     | 46/168               | 27.38     | 0.244    |
| 40 years or more                       | 595/840          | 70.83     | 108/153              | 70.59     | 0.951    |
| Undergraduate                          | 52/840           | 6.19      | 14/126               | 11.11     | 0.108    |
| Graduate                               | 352/840          | 41.90     | 47/126               | 37.30     |          |
| Postgraduate                           | 436/840          | 51.90     | 65/126               | 51.59     |          |
| Paid work                              | 693/840          | 82.50     | 95/251               | 37.85     | <0.001   |
| Employee                               | 528/836          | 63.16     | 52/98                | 53.06     | 0.205    |
| Student                                | 12/836           | 1.44      | 3/98                 | 3.06      |          |
| Independent without employees          | 101/836          | 12.08     | 18/98                | 18.37     |          |
| Employer                               | 48/836           | 5.74      | 7/98                 | 7.14      |          |
| Unemployed                             | 147/836          | 17.58     | 18/98                | 18.37     |          |
| COVID-19 in contacts                   | 790/840          | 94.05     | 91/251               | 36.25     | <0.001   |
| Death(s) due to COVID-19 in contacts   | 677/840          | 80.60     | 70/251               | 27.89     | <0.001   |
| DM, hypertension, or obesity           | 352/840          | 41.90     | 41/88                | 46.59     | 0.397    |
| Was vaccinated against influenza (2019–2020) | 474/840       | 56.43     | 24/48                | 50.00     | 0.383    |
| Was vaccinated against influenza (2020–2021) | 477/840       | 56.79     | 25/46                | 54.35     | 0.745    |
| Tetanus vaccine in the last five years | 230/840          | 27.38     | 10/49                | 20.41     | 0.060    |
| Tetanus vaccine more than five years ago | 271/840       | 32.26     | 16/49                | 32.65     |          |
| Has never received tetanus vaccine     | 35/840           | 4.17      | 6/49                 | 12.24     |          |
| Does not remember receiving the tetanus vaccine | 304/840   | 36.19     | 17/49                | 34.69     |          |

### Table 2 Characteristics of the surveyed population on intention to be vaccinated against COVID-19

| Characteristics                        | Hesitant No (50) | % (5.95) | Intends to be vaccinated or vaccinated No (790) | % (94.05) | P-value* |
|----------------------------------------|------------------|----------|-----------------------------------------------|-----------|----------|
| Male                                   | 16               | 32.00    | 252                                            | 31.90     | 0.969    |
| 40 years or older                      | 29               | 58.00    | 566                                            | 71.65     | 0.040    |
| Undergraduate                          | 6                | 12.00    | 46                                             | 5.82      | 0.034    |
| Graduate                               | 26               | 52.00    | 326                                            | 41.27     |          |
| Postgraduate                           | 18               | 36.00    | 418                                            | 52.91     |          |
| Paid work                              | 35               | 70.00    | 658                                            | 83.29     | 0.016    |
| Employee                               | 26               | 52.00    | 502                                            | 63.54     | 0.120    |
| Student                                | 0                | 0.00     | 12                                             | 1.52      |          |
| Independent without employees          | 8                | 16.00    | 93                                             | 11.77     |          |
| Employer                               | 1                | 2.00     | 47                                             | 5.95      |          |
| Unemployed                             | 15               | 30.00    | 132                                            | 16.71     |          |
| Has suffered COVID-19                  | 14               | 28.00    | 114                                            | 14.43     | 0.010    |
| COVID-19 in a relative living in the same home | 11            | 22.00    | 139                                            | 17.59     | 0.430    |
| COVID-19 in a relative living in a different home | 28            | 56.00    | 501                                            | 63.42     | 0.292    |
| COVID-19 in a neighbor                 | 18               | 36.00    | 287                                            | 36.33     | 0.963    |
| COVID-19 in friend or acquaintance     | 31               | 62.00    | 527                                            | 66.71     | 0.494    |
| Death(s) due to COVID-19 in a neighbor living in the same home | 2             | 4.00     | 15                                             | 1.90      | 0.306    |
| Death(s) due to COVID-19 in a different home | 11            | 22.00    | 277                                            | 35.06     | 0.059    |
| Death(s) due to COVID-19 in a friend or acquaintance | 26            | 52.00    | 485                                            | 61.39     | 0.187    |
| Death(s) due to COVID-19 in a neighbor | 15               | 30.00    | 182                                            | 23.04     | 0.260    |
| Death(s) due to COVID-19 in an acquaintance | 12            | 24.00    | 138                                            | 17.47     | 0.242    |
| Diabetes                               | 4                | 8.00     | 53                                             | 6.71      | 0.265    |
| Hypertension                           | 4                | 8.00     | 117                                            | 14.81     | <0.001   |
| Overweight or obesity                  | 14               | 28.00    | 277                                            | 35.06     | 0.596    |
| Was vaccinated against influenza (2019–2020) | 18            | 36.00    | 456                                            | 57.72     | 0.003    |
| Was vaccinated against influenza (2020–2021) | 15            | 30.00    | 462                                            | 58.48     | <0.001   |
| Was vaccinated against tetanus in the last five years | 11            | 22.00    | 219                                            | 27.72     | 0.109    |
| Was vaccinated against tetanus more than five years ago | 13            | 26.00    | 258                                            | 32.66     |          |
| Has never received tetanus vaccine     | 5                | 10.00    | 30                                             | 3.80      |          |
| Does not remember receiving the tetanus vaccine | 21            | 42.00    | 283                                            | 35.82     |          |

The population that most likely refused the vaccine
had not been vaccinated against influenza in previous seasons, a finding described by other researchers [23, 25]. Vaccine hesitancy was also linked to not knowing that handwashing prevents infection or refusal to use facemasks. We consider that these variables may be indicators of individual self-efficacy and the perceived effectiveness of health services. This path provides individuals with the necessary information and security to be active participants in decisions that concern their health. From a more general point of view, the vaccination process must consider political, economic, cultural, social, and religious contexts [26].

Other studies have found an association between vaccine rejection with age, sex, and socioeconomic level [9, 11–14, 22, 23, 27]. The direction of the association has been variable. These findings underline the complexity of vaccine determinants. As reported by other authors, our work detected that only the youngest age was associated with hesitancy among sociodemographic factors [11]. When adjusting the model for the significant or relevant variables, we did not find other demographic or clinical characteristics related to vaccine rejection.

Our study has several limitations. We followed the convenience and “snowball” methodology, so it does not necessarily represent the entire population sharing the same characteristics. Our study invited only academics, students, and administrative personnel of a public university with internet access; therefore, our results are not generalizable to the population who lacked this connection. By comparing the features of individuals who completed the survey with those who did not complete it, we found that those who had suffered from COVID-19 or had family members or acquaintances who had presented or died from this cause were more likely to complete it. Secondly, it was a cross-sectional study, so we do not know if there were changes in acceptance or rejection over time.

**Conclusion**

In contrast to previous studies conducted globally and in Latin America, our results revealed a low prevalence of vaccine hesitancy (6%). Hesitancy was significantly associated with fear of adverse effects, distrust of physician’s recommendations, lack of knowledge regarding handwashing, age younger than 40 years, refusal to use face masks, and not having received influenza vaccination during the two previous seasons. Vaccine promotion should improve communication with younger people, provide accurate information on adverse effects, and train health personnel for effective messaging.

---

**Table 3** Knowledge, attitudes, and perceptions of the study population about the COVID-19 vaccine

| Characteristic                                                                 | Hesitant (No = 50) | Intending to be vaccinated or vaccinated (No = 790) | P-value* |
|--------------------------------------------------------------------------------|--------------------|---------------------------------------------------|----------|
| Knows that a virus causes COVID-19. (No. (%))                                | 46 (92.00)         | 754 (95.40)                                       | 0.268    |
| Knows that SARS-CoV-2 is transmissible. (No. (%))                            | 49 (98.00)         | 790 (100)                                         | < 0.001  |
| Knows that washing hands prevents COVID-19. (No. (%))                        | 48 (96.00)         | 782 (98.99)                                       | 0.059    |
| Knows that people with comorbidities have a worse prognosis. (No. (%))      | 47 (94.00)         | 780 (98.73)                                       | 0.009    |
| Knows that face masks prevent COVID-19. (No. (%))                            | 47 (94.00)         | 765 (96.84)                                       | 0.279    |
| Is concerned about falling ill. (No. (%))                                    | 41 (82.00)         | 747 (94.56)                                       | < 0.001  |
| Experiences discomfort when wearing a mask. (No. (%))                        | 27 (54.00)         | 312 (39.49)                                       | 0.043    |
| Is ashamed when wearing a mask. (No. (%))                                    | 3 (6.00)           | 5 (0.63)                                          | < 0.001  |
| Trusts physician’s recommendations. (No. (%))                                | 31 (64.58)         | 739 (94.74)                                       | < 0.001  |
| Trusts family’s recommendations. (No. (%))                                   | 14 (29.17)         | 386 (49.49)                                       | 0.006    |
| Trusts friends’ recommendations. (No. (%))                                   | 14 (29.17)         | 347 (44.49)                                       | 0.038    |
| Fearful of adverse effects from the vaccine. (No. (%))                       | 6 (12.50)          | 17 (2.18)                                         | < 0.001  |
| Disbelief in the usefulness of the COVID-19 vaccine. (No. (%))               | 3 (6.25)           | 9 (1.15)                                          | 0.004    |
| Considers that the COVID-19 vaccine is unnecessary. (No. (%))               | 8 (1.03)           | 6 (12.50)                                         | < 0.001  |
| Fear of adverse effects. (No. (%))                                           | 34 (70.83)         | 305 (39.10)                                       | < 0.001  |
| Has had bad experiences with other vaccines. (No. (%))                      | 18 (37.50)         | 190 (24.36)                                       | 0.042    |
| Will never vaccinate their children. (No. (%))                               | 8 (16.67)          | 12 (1.54)                                         | < 0.001  |
| Refuses to use face masks. (No. (%))                                         | 1 (2.00)           | 2 (0.25)                                          | 0.045    |

**Table 4** Factors associated with COVID-19 vaccine hesitancy

| Characteristic/Attitude/Condition | PR | CI 95% | P-value* |
|----------------------------------|----|--------|----------|
| Fear of adverse effects          | 4.42 | 2.58–7.56 | < 0.001  |
| Distrusts physician’s recommendations | 3.99 | 2.27–6.99 | < 0.001  |
| Does not know that washing hands prevents COVID-19 | 3.64 | 1.84–7.21 | < 0.001  |

**Socio-demographic**

- Under 40 years of age: 2.15 1.30–3.55 0.003
- 40 years of age or older: Ref - -
- Refuses to use face masks: 2.11 1.29–3.43 0.001
- No 2019–2020 influenza vaccination: 2.08 1.14–3.79 0.017
- No person has died due to COVID-19 among family members, neighbors, or acquaintances: 1.39 0.85–2.28 0.196
Acknowledgements
The authors acknowledge the anonymous participants.

Authors’ contributions
NMR, MRA, MLCC, MMH, RPP, SPL, and LGG participated in the study conception and design; NMR and MRA acquired data; NMR, MRA, DRZ, MEJC, MLCC, GMN, GCP, EFG, LFR, GDS, MMH, ACS, RPP, and SPL analyzed and interpreted data; NMR, NRA, and LGG contributed to the writing of the manuscript; DRZ, MEJC, MLCC, GMN, GCP, EFG, LFR, GDS, MMH, ACS, RPP, and SPL critically revised the manuscript for important intellectual content. All the authors reviewed the manuscript and granted their final approval for this version to be published. LGG is the corresponding author.

Funding
Not applicable.

Availability of data and materials
Data and materials are available in the manuscript and tables.

Declarations
Ethics approval and consent to participate
The study was carried out according to the relevant guidelines and regulations of the Helsinki Declaration and received approvals from the ethics, research, and bioethics committees of the National Autonomous University of Mexico (Approval Registry FM/DI/075/2021). Informed consent was obtained from all the participants and/or legal guardian(s).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México 2 Progyma Universitario de Investigación en Salud, Universidad Nacional Autónoma de México Ciudad Universitaria, Ciudad de México, México 3 Hospital Infantil de México “Federico Gómez”, Ciudad de México, México 4 Instituto Nacional de Cardiología, Ciudad de México, México 5 Posgrado en Geografía, Universidad Nacional Autónoma de México, Ciudad Universitaria, Ciudad de México, México 6 Universidad Nacional Autónoma de México, Ciudad de México, México 7 Instituto de Investigaciones en Matemáticas Aplicadas y en Sistemas, Universidad Nacional Autónoma de México, Ciudad de México, México 8 Instituto Nacional de Enfermedades Respiratorias, Ciudad de México, México 9 Instituto Nacional de Salud Pública, Av. Universidad # 655, Col. Sta. María Ahsucatlán, C.P. 62100 Cuernavaca, Morelos, México

Received: 21 April 2022 / Accepted: 16 September 2022
Published online: 04 October 2022

References
1. Hannah Ritchie E, Mathieu L, Rodés-Guirao C, Appel C, Giattino E, Ortiz-Ospina J, Hasel B, Macdonald, Diana Betekian and Max Roser (2020). “Coronavirus Pandemic (COVID-19)” Published online at OurWorldInData.org https://ourworldindata.org/coronavirus. Accessed April, 2022.
2. World Health Organization. Vaccine hesitancy: a growing challenge for immunization programmes.https://www.who.int/news-room/spotlight/ten-theorets-of-global-health-in-2019. Accessed April 2022.
3. World Health Organization. COVID-19 vaccine tracker and landscapehttps://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed April, 2022.
4. Grupo Tecnico Asesor de Vacunacion C. Salud Publica Mex. 2020;63(2);Mar–Abr;288–309.
5. Cortés-Alcalá R, López-Gatell H, López-Ridaura R, Gómez-Torres R, Albaricofo X, Vézquez-Goicoe M, et al. Mexican guideline for SARS-CoV-2 vaccination for prevention of COVID-19 in Mexico (Política nacional rectora de la vacunación contra el SARS-CoV-2 para la prevención de la COVID-19 en México. Donorco covid.gov.mv/wordpress/docume-mentos-de-consulta/. Accessed March, 2022.
6. MacDonald NE. SAGE Working Group on Vaccine Hesitancy. Vaccine hesi-tancy: Definition, scope and determinants. Vaccine. 2015 Aug 14;33(34):4161- 4. doi: https://doi.org/10.1016/j.vaccine.2015.04.036. Epub 2015 Apr 17. PMID: 25896383.
7. Shaheel CS, Mujeeb AA, Mirza MS, Chaudhry B, Khan SJ. Global COVID-19 Vac-cine Acceptance: A Systematic Review of Associated Social and Behavioral Factors. Vaccines (Basel). 2022;10(1).
8. Sallam M, Al-Sanafi M, Sallam M. A Global Map of COVID-19 Vaccine Acceptance Rates per Country: An Updated Concise Narrative Review. J Multidiscip Healthc. 2022;15:21–45.
9. Nehal KR, Steendam LM, Campos Ponce M, van der Hoeven M, Smit GSA. Worldwide Vaccination Willingness for COVID-19: A Systematic Review and Meta-Analysis. Vaccines (Basel). 2021;9:18.
10. Patwary MM, Alam MA, Bardsen M, Disha AS, Haque MZ, Billah SM, et al. COVID-19 Vaccine Acceptance among Low- and Lower-Middle-Income Countries: A Rapid Systematic Review and Meta-Analysis. Vaccines (Basel). 2022;10(3).
11. Tolo SA, Faria de Moura Villela E, Saiu CS, Chen WS, Pengpid S, Hasan MT, et al. Factors Affecting COVID-19 Vaccine Acceptance: An International Survey among Low- and Middle-Income Countries. Vaccines (Basel). 2021;9(5).
12. Urunguaga-Pastor D, Bendeuz-Quispe G, Herrera-Añezo P, Uyen-Cateriano A, Toro-Huamanchumo CJ, Rodríguez-Morales AJ, et al. Cross-sectional analysis of COVID-19 vaccine intention, perceptions and hesitancy across Latin America and the Caribbean. Travel Med Infect Dis. 2021;41:102059.
13. Carnalla M, Basto-Abreu A, Stern D, Bautista- Arredondo S, Shama-Levy T, Alpuche-Aranda CM, et al. Acceptance, refusal and hesitancy of Covid-19 vaccination in Mexico: Emsanut 2020 Covid-19. Salud Publica Mex. 2021;63(5):598–606.
14. Delgado-Gallegos JL, Padilla-Rivas GR, Zúñiga-Volante E, Avilés-Rodríguez G, Arellanos-Soto D, Gastelum-Arias L, et al. Determinants of COVID-19 Vaccine Hesitancy: A Cross-Sectional Study on a Mexican Population Using an Online Questionnaire (COV-AHQ). Front Public Health. 2021;9:726690.
15. Universidad Nacional Autónoma de México. Instituto Nacional de Salud Pública. Encuesta sobre conocimientos, actitudes y prácticas relacionadas con COVID-19; las vacunas y la vacunación. -MX. Consultado noviembre, 2021. https://surveys.c3.unam.mx/36168/lang-es.
16. Tuong J, Bakshi S, Waisim A, Ahmad M, Majid U. What factors promote vac-cine hesitancy or acceptance during pandemics? A systematic review and thematic analysis. Health Promot Int. 2022;37(1).
17. Lee SW. Methods for testing statistical differences between groups in medi-cal research: statistical standard and guideline of Life Cycle Committee. Life Cycle. 2022;2:1.
18. Wouters DJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ, Teeer-awattananon Y, et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet. 2021;397(10278):1023–34.
19. Sallam M. COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates. Vaccines (Basel). 2021;9(2).
20. Neumann-Böhme S, Vangriese NE, Sabat I, Barros PP, Brouwer W, van Exel J, et al. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. Eur J Health Econ. 2020;21(7):977–82.
21. Bows F, Atzubasi MS, Shah UJ, Ali-Abd-Alaiziq AA, Shah Z. A Scoping Review to Find Out Worldwide COVID-19 Vaccine Hesitancy and Its Underlying Determinants. Vaccines (Basel). 2021;9(11).
22. Joshi A, Kaur M, Kaur R, Grover A, Nash D, El-Mohandes A. Predictors of COVID-19 Vaccine Acceptance, Intention, and Hesitancy: A Scoping Review. Front Public Health. 2021;9:698111.
23. Bows F, Atzubasi MS, Shah UJ, Ali-Abd-Alaiziq AA, Shah Z. A Scoping Review to Find Out Worldwide COVID-19 Vaccine Hesitancy and Its Underlying Determinants. Vaccines (Basel). 2021;9(11).
24. Wong LP, Alias H, Wong PF, Lee HY, AbulBaker S. The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay. Hum Vaccin Immunother. 2020;16(8):2204–14.
25. Nindrea RD, Usman E, Katar Y, San NP. Acceptance of COVID-19 vaccination and correlated variables among global populations: A systematic review and meta-analysis. Clin Epidemiol Glob Health. 2021;12:100899.
26. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington (DC)2001.
27. Robinson E, Jones A, Lesser I, Daly M. International estimates of intended uptake and refusal of COVID-19 vaccines: A rapid systematic review
and meta-analysis of large nationally representative samples. Vaccine. 2021;39(15):2024–34.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.